A novel immunoassay for improved sensitivity and minimal bias
B-type natriuretic peptide (Brain natriuretic peptide, BNP) is an acknowledged marker of heart failure (HF) widely used in clinical practice for HF diagnosis and patient management.
The majority of BNP assays are designed as sandwich-type immunoassays utilizing two mAbs specific to distantly located epitopes. In commercially available assays at least one of these two antibodies is specific to the ring structure, while the other is usually specific to the C-terminus of the BNP molecule. Recent data regarding BNP instability in circulation suggests that immunoassays utilizing at least one MAb specific to the terminal epitope could underestimate the real BNP content in the blood sample.
CLINICAL UTILITY OF BNP
- Identification or exclusion of heart failure (HF)
- Assessment of the severity of HF
- Prognosis of the disease development
- Monitoring of drug therapy in the presence of HF
BENEFITS OF SES-BNP™ ASSAY
- Equally recognizes proBNP, BNP and their truncated forms
- Enables extremely high sensitivity (1 pg/ml)
- Targeted to a stable epitope 11-17 aar of BNP
Monoclonal Antibodies
Antigens
SES-BNP™ is a trademark or a registered trademark of HyTest Ltd.
Problem – In most commercially available assays, at least one mAb is specific to the C-terminus of the BNP molecule. Since BNP in circulation is often partially truncated, this type of assay may not detect all BNP forms present in blood.
Solution – In our proprietary SES-BNP assay the capture antibody (mAb 24C5) is specific to the stable ring part of the BNP molecule. The detection antibody (mAb Ab-BNP2) is specific to the complex formed by capture antibody and BNP (or proBNP). Detection antibody does not recognize BNP or capture antibody separately, the epitope for antibody binding is only formed when these two molecules are in a complex. In the SES-BNP assay the accuracy and specificity are not compromised by truncation of BNP allowing reliable quantitation of the biomarker.